Alembic Pharmaceuticals has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid
Formulation Facility (F-I) located at Panelav. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17 July 2024 to 26 July 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
